影响万科米辛平均度的因素;在非临界护理沙特患者中的一种人口药动力学模型
Aymen Ali Alqurain1, Laila Nasser Alrashidi2, Shatha Khalid Aloraifej2
1Department of Clinical Practice, College of Pharmacy, Northern Border University, Rafha, 91911, Saudi Arabia.
Drug design, development and therapy
|December 26, 2024
概括
这项研究发现,肌素清除率 (CrCl) 和C反应蛋白 (CRP) 显著影响沙特成年患者的万科米辛水平. 了解这些因素对于优化万科米辛剂量和患者的治疗结果至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 传染性疾病 传染性疾病
背景情况:
- 范科米是对抗甲素耐药黄金葡萄球菌 (MRSA) 感染的关键抗生素.
- 范科米的药理动力学在老年人中可能有很大差异.
- 在沙特成年人群中,关于万科米辛的药理动力学数据有限.
研究的目的:
- 开发沙特阿拉伯成年患者的万科米辛人口药动力学 (Pop-PK) 模型.
- 为了确定影响万科米辛最低度的患者特征.
- 为了优化医疗病房环境中的万科米辛治疗.
主要方法:
- 一个多中心的回顾性研究成年患者 (≥40岁) 接受vancomycin.
- 使用非线性混合效果建模 (Monolix) 来构建Pop-PK模型.
- 分析的共同变量包括年龄,性别,体重,CRP,血清肌素,CrCl和白蛋白.
主要成果:
- 最终的Pop-PK模型采用了带有线性淘汰的单间分布.
- 鉴定出肌素清除率 (CrCl) 和C-反应蛋白 (CRP) 是影响万科胺素清除率的显著共变量.
- 较高的CRP和较低的CrCl水平与增加的万科米辛最低度有关.
结论:
- 在万科米辛的最低度中存在显著的个体间变异.
- 在沙特成年医疗患者中,CrCl和CRP是影响万科米辛药理学的关键因素.
- 波普-PK模型为个性化的万科米辛剂量策略提供了洞察力.
相关概念视频
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
101
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
101
01:12Analysis of Population Pharmacokinetic Data
190
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
190
01:24One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
221
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
221
01:15Drug Concentration Versus Time Correlation
513
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
513
01:25Clearance Models: Compartment Models
36
Clearance measures drug elimination from the central compartment, including plasma and highly perfused organs like kidneys and liver. Its calculation varies depending on pharmacokinetic models and administration routes. The one-compartment model, for instance, portrays the pharmacokinetics of polar drugs such as aminoglycoside antibiotics administered intravenously and readily excreted in urine. In this case, clearance is influenced by the terminal rate constant (λz) and the total volume...
36
00:54Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
34
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
34